Author :
Qazi Saba, Akshay Rathore, Anuradha Yadav, Saplin Pradhan, Sylvia Waikhom, Achom Uma, Qazi Saba, Akshay Rathore, Anuradha Yadav, Saplin Pradhan, Sylvia Waikhom, Achom Uma
Volume :
13
Issue :
2
Abstract :
Background: Myofascial pain syndrome (MPS) is characterized by muscle pain and tenderness, often associated with myofascial trigger points (MTrPs). These MTrps can cause referred pain and muscle dysfunction, such as in the masseter. Platelet-rich plasma (PRP) therapy has emerged as a treatment for myofascial pain due to its regenerative properties, while corticosteroids like dexamethasone are commonly used for their anti-inflammatory effects. This study aims to compare the efficacy of PRP and dexamethasone injections in treating MTrPs in the masseter muscle.Materials and Methods: This study involved 30 participants (age 18-40) with active MTrPs in the masseter muscle. Participants were randomly assigned to two groups to receive either dexamethasone (Group 1, Dexamethasone =15) or platelet-rich plasma (Group 2, PRP 15). Pain levels were measured using the Visual Analog Scale (VAS), and functional outcomes were assessed via Maximum Interincisal Opening (MIO) and Pain Perception Index (PPI) at baseline, Day 0, Day 5, Day 15, and one monthResults: Both treatments significantly reduced pain and improved functional outcomes (MIO and PPI) over time. No significant differences were found between the PRP and dexamethasone groups in pain reduction or functional improvements (p > 0.05).Conclusion: PRP and dexamethasone are equally effective in managing pain and improving function in MPS. Larger studies with longer follow-ups are needed to confirm these findings.
Keyword :
Myofascial pain syndrome, Myofascial trigger points, Platelet-rich plasma, Dexamethasone, Masseter muscle, Pain relief, Functional recovery, Regenerative therapy.